Can Brigatinib/Brigatinib be taken together with 9291?

9291 usually refers to osimertinib mesylate tablets in the country. In the current study, Brigatinib was found to be effective in vitro and in vivo against cells harboring the C797S/T790M/activating mutation (triple mutation). Initial computational simulations showed that brigatinib fit into the ATP-binding pocket of triple-mutated EGFR. The efficacy of brigatinib is significantly enhanced by combining it with an anti-EGFR antibody due to the reduction in surface and total EGFR expression. Therefore, the combination therapy of brigatinib and the anti-EGFR antibody osimertinib is a strong candidate to overcome triple mutated EGFR. In some aspects, the simultaneous use of brigatinib and osimertinib may be necessary for some patients to better control the disease and improve the effectiveness of treatment, but treatment must be carried out in accordance with the recommendations of your doctor.